AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03263546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks.
Study NCT05487521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and or prednisolone
Description: we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
Study NCT01149317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Weekly acupuncture treatment for up to 14 weeks to augment usual care
Study NCT03253042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WBV exercise program
Description: The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
Study NCT03253042 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham WBV exercise program
Description: The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
Study NCT03212898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anticoagulation care
Description: Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
Study NCT03041688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03041688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT03041688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT03041688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03041688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO
Study NCT03041688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT00911118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated, image-guided, intensity-modulated external beam radiation
Description: A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if \< 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
Study NCT03044613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg or 1 mg/kg administered IV
Study NCT03044613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: 80mg administered IV
Study NCT03044613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: standard care dose
Study NCT03044613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: standard care dose
Study NCT03044613 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: standard care dose
Study NCT01971541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: A validated 8-week group program that teaches mindfulness meditation
Study NCT01971541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: A validated group program of PTSD treatment, which focuses on cognitive processing.
Study NCT02005367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Recovery-Horticulture
Description: Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures.
Study NCT02005367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Recovery-Art/Music
Description: Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
Study NCT03866655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OWise
Description: OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
Study NCT03309878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV
Study NCT03309878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01096316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Care Management
Description: The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
Study NCT00287222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/KG I.V. every 21 days
Study NCT00287222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg orally every day
Study NCT01762553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The TEA intervention
Description: TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
Study NCT04508881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Glaucoma Valve
Description: To compare the prevalence of postoperative hypotony between the 2 arms
Study NCT01160276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine+colchicine
Description: the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
Study NCT01160276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
Study NCT01514019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acebutolol
Description: Acebutolol
Study NCT01514019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule(Capsules filled up with lactose)
Study NCT03500159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125 200 mg
Description: Synthetic SHIP1 activator
Study NCT03500159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appearance and weight matched tablets without the active product ingredient
Study NCT04083976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib oral tablets.
Study NCT03777943 — intervention group
Intervention type: PROCEDURE
Intervention: Sampling peritoneal tissue
Description: Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
Study NCT02768493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg of 0.15% ropivacaine
Description: Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
Study NCT02768493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 ml/kg of 0.15% ropivacaine
Description: Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
Study NCT04787224 — intervention group
Intervention type: OTHER
Intervention: immediate implant with vestibular socket therapy
Description: A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft \[75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.
Study NCT02088450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active treatment with nitrendipine (10-40 mg/day).
Description: If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
Study NCT02088450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active treatment with nitrendipine (10-40 mg/day).
Description: If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
Study NCT03103126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined resistance exercise and walking
Description: Combined resistance exercise and walking
Study NCT06394986 — intervention group
Intervention type: PROCEDURE
Intervention: Hemodialysis session
Description: Change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session will be explored.
Study NCT00887549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Induction Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
Study NCT00887549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Induction Therapy: 75 mg/m\^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
Study NCT02253615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Machines exercises
Description: Resistance training in pneumatic machines.
Study NCT02253615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic exercises
Description: Resistance training with elastic tubes.
Study NCT00759161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: AN2728 Ointment, 5%, twice daily for 4 weeks
Study NCT00759161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Ointment Vehicle
Description: AN2728 Ointment Vehicle, twice daily for 4 weeks.
Study NCT00103168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400 mg/day for 2 years
Study NCT03846050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAC feedback/warning
Description: Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
Study NCT03846050 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No BAC feedback/warning
Description: Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
Study NCT00325715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 201904
Study NCT00325715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Study NCT03015766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure therapy
Description: Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
Study NCT03015766 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham auricular acupressure therapy
Description: The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
Study NCT02832934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and \<4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study NCT02832934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study NCT02383875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opticourses
Description: An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
Study NCT01794000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally
Study NCT01794000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03222700 — intervention group
Intervention type: PROCEDURE
Intervention: surgical procedure
Description: In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
Study NCT02907515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cm-loc attachment
Description: cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
Study NCT02907515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ball attachment
Description: ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
Study NCT00366002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
Study NCT02222935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Exercise Training
Description: Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
Study NCT02222935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Back exercise program
Description: Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
Study NCT02869399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention in addition to standard recommendations
Description: The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~* avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~* increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~* eat mostly food of plant origin~* eat lean meat, limit intake of red meat and avoid processed meat~* increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~* avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries
Study NCT02314052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-MYC
Description: Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety
Study NCT02748863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
Study NCT02748863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 2 mL form
Description: Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
Study NCT02748863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 1 mL form
Description: Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
Study NCT02624271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples analysis
Description: Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
Study NCT01618032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA
Description: High velocity and low amplitude manipulation in traction of subtalar jonit
Study NCT01618032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MWM
Description: Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing